Background. Little is known about the immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereafter, "varicella vaccine") in frail nursing homes residents nor about immune phenotypes associated with a response.
Herpes zoster (HZ), a painful neurocutaneous syndrome caused by reactivation of latent varicella-zoster virus (VZV), can lead to significant morbidity [1] . This syndrome can be complicated by postherpetic neuralgia, a painful condition that can last for months [2] . In a US population-based study conducted between 1996 and 2001, the incidence of HZ was estimated to be 3.6 cases per 1000 person-years [3] . Both the incidence and severity of HZ and postherpetic neuralgia increase with advanced age, such that >60% of reported cases occur in persons aged >50 years [2] [3] [4] [5] . This age-associated increase in HZ correlates with a decline in VZV-specific T-cell-mediated immunity, a phenomenon characteristic of immunosenescence [6] . It is recommended that people aged >60 years receive live-attenuated VZV-containing vaccine (hereafter, "varicella vaccine"), which significantly reduces the incidence of HZ with a concomitant increase in VZV-specific T-cell-mediated immunity [7, 8] . The efficacy of varicella vaccine in preventing HZ and postherpetic neuralgia in those aged 60-79 years was 51% and 67%, respectively [8] [9] [10] . However, only 26% of vaccinees aged >80 years were protected from postherpetic neuralgia, indicating an age-related reduction in vaccine efficacy [11] .
While the cellular mechanisms responsible for controlling VZV reactivation are not well understood, cytotoxic CD8 + T cells are thought to play a major role, along with CD4 + T-helper cells and major histocompatibility complex class II-expressing satellite glial cells [12] . It is possible that the specific immunosenescence-related alterations in the T-cell pool, such as elevated frequencies of senescent and terminally differentiated T-cell subsets and a reduction in the frequency of naive T cells, could impact the ability of frail elderly persons to develop vaccine-specific immune responses [13] [14] [15] [16] [17] . We have previously shown that cellular markers of immunosenescence, including increased frequencies of cytomegalovirus (CMV)-specific CD4 + T cells and regulatory T cells (Tregs) [18, 19] , were predictive of respiratory viral infection in an aged cohort [13] . As such, measuring these markers in individuals before vaccination may be a strategy to determine varicella vaccine responsiveness [20] . Given their advanced age, multiple comorbid conditions, and immunosenescence, elderly residents of nursing homes experience a significant HZ burden [21] . Although there are no rigorous estimates of HZ incidence, recent reports suggest that rates of hospitalization and length of stay are significantly greater for residents with HZ as compared to residents hospitalized for other conditions [22] . Furthermore, there is a paucity of data on varicella vaccine efficacy in frail elderly nursing home residents. We therefore sought to assess immunogenicity, as measured by an interferon γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assay, following administration of the Oka/Merck varicella vaccine. We compared immunogenicity in a cohort of elderly nursing home residents to that of community-dwelling seniors. Furthermore, we explored the relation between varicella vaccine efficacy and frailty, multimorbidity, or baseline cellular markers of immunosenescence.
PATIENTS AND METHODS

Participants and Study Design
Nursing home residents (n = 190) from 18 facilities in Hamilton and Toronto, Canada, were recruited between January 2012 and February 2014 for the study. The elderly participants were between 80 and 102 years of age; 81% were women, and all had ≥1 comorbidity.
Frailty was operationalized using the frailty index score, a reproducible scale that has been validated in the nursing home setting [23, 24] . Items that compose the frailty index include the presence of comorbidities, functional status, and physical and neurological signs revealed by physical examination. The frailty index is calculated as the number of deficits divided by the number of variables considered; for example, a person with 7 deficits would have a frailty index score of 0.1 (7/70). Comorbidity status was operationalized using a major condition score, in which comorbidities were assigned a point value and summed to provide the final score. Scores were assigned as follows: 1 point: myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary disease, connective tissue disease, ulcerative disease, mild liver disease, or diabetes without end organ damage; 2 points: hemiplegia, moderate or severe renal disease, diabetes with end organ damage, any tumor, leukemia, or lymphoma; 3 points: moderate or severe liver disease; 6 points: metastatic solid tumor or AIDS. Community-dwelling seniors (n = 50) from the same geographical location were recruited between February and May 2012 as a comparison group. They were 60-75 years of age; 64% were women, and no participant had >1 comorbidity. Written informed consent was obtained from all participants or their legally appointed guardian. The study protocol and consent procedures were approved by the McMaster Research Ethics Board and the participant's nursing homes.
All participants received Oka/Merck varicella vaccine (≥19 400 plaque-forming units; Zostavax, Merck Group) subcutaneously. Heparinized venous blood specimens were collected before (visit 1) and 6 weeks after (visit 2) vaccination and processed within 8 hours of collection. Peripheral blood mononuclear cells (PBMCs) were isolated using a validated protocol [25] and cryopreserved in 10% dimethyl sulfoxide (DMSO)/ human AB serum (Sigma/Lonza) freezing medium. The samples were stored at −160°C in freezer containing vapor-phase liquid nitrogen.
IFN-γ ELISPOT Assay
The IFN-γ ELISPOT assays were performed as described in the protocol by Smith et al [26] . Briefly, cryopreserved PBMCs were thawed at 37°C in prewarmed complete Roswell Park Memorial Institute (cRPMI) medium supplemented with 10% heat-inactivated fetal bovine serum, 10 mM HEPES buffer (Gibco), 1 mM L-glutamine (Gibco), 100 µg of penicillin per mL, 100 U of streptomycin (Gibco BRL) per mL, and β-mercaptoethanol (Sigma)). Cells were washed and resuspended in cRPMI medium and were quantified using a Cellometer Auto 2000 cell counter (Nexelom). The concentration of cells was then adjusted to 10 7 cells/mL for assay setup.
Ninety-six-well Multiscreen-IP membrane plates (Millipore) were coated with anti-human recombinant IFN-γ monoclonal antibody overnight at 4°C. The following day, wells were washed with phosphate-buffered saline and blocked with cRPMI medium. Antigens were diluted appropriately in cRPMI medium and added to the wells. The VZV antigen was a clarified supernatant preparation from lysed, UV light-inactivated VZV-infected MRC-5 cells. The same process performed using uninfected MRC-5 cells produced the negative control antigen. A pool of CD8 + T cells specific to peptides for CMV, Epstein-Barr virus, and influenza virus, referred to as the CEF peptide pool (Miltenyi), was used as a positive control at a final concentration of 5 µg/mL. Additionally, cells were incubated with dimethyl sulfoxide diluted in cRPMI medium as a negative control. A 50-µL cell suspension containing 5 × 10 5 PBMCs was added to each well with 50 µL of appropriately diluted antigen, and plates were incubated for 20 hours at 37°C. Plates were subsequently washed and incubated with a biotinylated anti-human recombinant IFN-γ antibody overnight at 4°C. The next day, ELISPOT assays were developed with streptavidin-alkaline phosphatase conjugate diluted in ELISPOT wash buffer (Pierce) and substrate NBT/BCIP. The resulting spots were enumerated using the ImmunoSpot Image Analyzer system and counting software (Cellular Technologies). VZV-specific responses were reported as absolute VZV spot-forming cells (SFCs) per 10 6 PBMCs (calculated as the SFC count in response to VZV antigen minus the SFC count in response to MRC-5 cell antigen).
Treg Staining
PBMCs were thawed and placed immediately into 37°C prewarmed cRPMI medium. Cell count and viability were assessed using the Cellometer Auto 2000. Cells were aliquoted (1 × 10 6 -2 × 10 6 cells/well) into a round-bottomed 96-well plate and stained with the following anti-human antibodies purchased from eBiosciences; CD3-FITC, CD4-Pacific Blue, CD8-Alexa Flour 700, and CD127-PerCP Cy5.5 (all from eBiosciences) and CD25-PE and FoxP3-APC (both from BD Biosciences).
Following surface staining, cells were permeabilized using the FoxP3 buffer set (eBiosciences) and stained with FoxP3-APC-conjugated antibody. Analyses of Tregs was performed using LSR II and FlowJo software.
Intracellular Cytokine Staining
PBMCs were thawed and placed immediately into 37°C prewarmed cRPMI medium and rested overnight in a 37°C incubator. The cells were subsequently harvested and counted, and viability was assessed using the Cellometer Auto 2000. Cells were aliquoted (2 × 10 6 -2.5 × 10 6 cells/well) into round-bottomed 96-well plates; CMV pp65-specific peptides were added to a final concentration of 1 µg/mL and incubated for 1 hour at 37°C. DMSO diluted in cRPMI medium was used as a peptide-nonspecific negative control. Brefeldin A (BD Biosciences) was added to the cell/peptide mixture in accordance with the manufacturer's instructions, and the mixture was incubated for an additional 4 hours. At this point, cells were pelleted and washed in 10 µM ethylenediaminetetraacetic acid. A cocktail comprising anti-human CD3-Qdot 605 (Molecular Probes), CD8-PerCP Cy5.5, and CD4-Alexa Flour 700 (eBiosciences) surface antibodies was created for cytokine analysis. Cells were then permeabilized with Cytofix/Cytoperm (BD Biosciences), and intracellular IFN-γ was identified using antihuman IFNγ-APC (BD Biosciences). Fluorescence data were acquired using an LSRII flow cytometer (BD Biosciences). Data were analyzed using FlowJo. A positive response was measured as an IFN-γ frequency that was >0.05 SFCs and 3-fold above the DMSO background level.
Statistical Analysis
The statistical significance of differences in donor age, major condition score, and frailty index was tested using the Student t test and that of difference based on sex was determined using the Fisher exact test. Since the vaccine-related measures were not found to be normally distributed (according to qualitative assessment by a normal QQ-plot), they were tested using the Wilcoxon signed rank test. Tests for the effect of age, sex, frailty, comorbidity (major condition score), or cellular markers of immunosenescence on the observed VZV immune response were performed by univariate linear regression. For these analyses, the fold change in VZV immune response was log transformed for the regression residuals to approximate normality. To test the hypothesis that cellular markers of immunosenescence are correlated to the varicella vaccine response in elderly nursing home residents, we measured the frequency of CD4 + , CD8 + , and CD4 + Tregs, as well as the frequency of CMV-specific IFN-γ-producing T cells. The frequency of the cellular markers were binned into quartiles (quartile 1, minimum to 24th percentile; quartile 2, 25th-49th percentiles; quartile 3, 50th-74th percentiles; and quartile 4, 75th percentile to the maximum) and treated as categorical independent variables in each regression model. Univariate analyses indicated that significant differences between quartiles existed only for Treg frequency and CMV-specific CD4 + T-cell reactivity. Therefore, these markers were tested in a single multivariate model that included age, sex, and CMV-specific Treg and CD4 + T-cell reactivity quartile. The VZV response, as measured by IFN-γ production, was reported as a log-transformed fold-change difference before and after vaccination and was stratified into quartiles. All statistical analyses were performed in R v3.0.1.
RESULTS
A total of 190 elderly participants aged 80-102 years from 18 nursing homes in Ontario were recruited in our study. Fifty community-dwelling seniors (age range, 60-75 years) from the same geographical region comprised the comparison cohort. The elderly residents of nursing homes exhibited significantly greater frailty (based on the Rockwood frailty index) and multimorbidity in comparison to the community-dwelling seniors (Table 1 ). All participants were administered the live-attenuated varicella vaccine, and no adverse events were observed within either population, indicating that the vaccine can be safely administered to frail patients. The patients' PBMCs were analyzed by an IFN-γ ELISPOT assay before (visit 1) and 6 weeks after (visit 2) immunization. Analyses of VZV-specific T-cell-mediated immunity, reported as IFN-γ SFCs at visit 1, showed an age-dependent decline that was most pronounced in the nursing home cohort ( Figure 1A ). These results corroborate Data are mean (range), unless otherwise indicated. There was no effect of age, sex, comorbidities (major condition score) or frailty in the log fold change response to the varicella vaccine when tested by univariate linear regression. There was also no difference between participant groups for the log fold change response in multivariate models that were adjusted by age, sex, comorbidities, frailty and/or baseline vaccine response.
Abbreviation: VZV, varicella-zoster virus. a Differences in donor age, major condition score, and frailty were tested the using Student t test, and difference in sex were tested using the Fisher exact test. Since the vaccine-related measures were not found to be normally distributed (according to qualitative assessment by normal QQ-plot), they were tested using the Wilcoxon signed rank test. P values of >. previous reports that have shown an age-dependent waning of VZV immunity in old individuals [9, 10] . Furthermore, VZV immunity before vaccination was significantly more compromised in the elderly residents of nursing homes than in the community-dwelling seniors, with median numbers of IFN-γ SFCs of 33 and 58 (P < .001; Table 1 ). Following vaccination, the elderly residents of nursing homes elicited lower absolute VZV responses in comparison to the community-dwelling seniors (median number of IFN-γ SFCs, 63 vs 102; P < .001; Table 1 ). However, the fold-change difference in the VZV response before vaccination and at follow-up week 6 revealed no significant difference between elderly residents of nursing homes (median, 1.8; IQR, 1.2-3.2) and community-dwelling seniors (median, 1.5; IQR, 1.2-2.3; Table 1 and Figure 1B ). This suggests that, despite initially lower numbers of VZV-specific cells in the nursing home patients, VZV vaccination boosted virus-specific immunity as measured by IFN-γ SFCs. Within each group, there was no significant effect of age, sex, frailty, or multimorbidity on the observed baseline and follow-up responses or the fold-change differences in the vaccine response (data not shown).
In a previous report examining the nursing home population, we discovered that elevated frequencies of CMV-specific CD4 + T cells and CD4 + Tregs were associated with an increased risk of respiratory virus infection. To determine whether these immune markers also correlated with the level of VZV booster responses in our patient cohort, we measured the global frequency of CD4 + , CD8 + , regulatory (CD4 + FoxP3 + ), and CMV-specific T cells in the baseline samples. The fold-change response did not correlate with the frequency of CD4 + and CD8 + T cells or the frequency of CMV-specific CD8 + T cells (Table 2) . However, consistent with our previous report, the VZV booster responses were significantly lower with higher quartile of Treg frequency and CMV-reactive CD4 + T-cell frequency (Table 2 ). This suggests that the accumulation of CMV-specific CD4 + T cells and Tregs with age might impact varicella vaccine responsiveness.
DISCUSSION
We sought to specifically characterize the varicella vaccine response in elderly residents of nursing homes and compare it to the response in community-dwelling seniors. We found that elderly residents of nursing homes had VZV booster responses that were comparable to those of the community-dwelling seniors and that age, sex, frailty, and comorbidity (based on the major condition score) within each cohort did not significantly affect vaccine responsiveness. The absolute levels of VZV responses following vaccination were lower in the nursing home cohort in comparison to the community-dwelling seniors (median IFN-γ SFCs, 63 vs 102; P < .001). We cannot establish with certainty whether vaccine-induced VZV immunity would confer protection from HZ onset and severity in this cohort, and we acknowledge this as a limitation. However, we can postulate that, on the basis of data from a population-based study in which senior vaccinees with an average VZV response of 72.5 IFN-γ SFCs did not develop HZ [27] , the immune response elicited by the vaccine in our study could be efficacious.
In keeping with what has been previously documented about the negative effect of age on vaccine responsiveness [28, 29] , we found a significant reduction in the number of IFN-γ-secreting leukocytes following vaccination in nursing home residents as compared to community-dwelling seniors. This trend was also noted between the 2 cohorts before vaccination, indicating that elderly residents of nursing homes have lower numbers or fewer VZV-specific memory T cells than community-dwelling seniors. Given that our population was a homogeneous frail nursing home population with comorbidity, the average age of which was 89 years, with a range of 80 to 102 years, the lack of an age-dependent response in this particularly narrow spectrum of the aged population may not be unexpected.
Interestingly, the elderly residents of nursing homes can boost VZV immunity following immunization with VZV live vaccine with a magnitude comparable to that of healthy community dwellers, suggesting that this cohort does not have an inherent impaired immune response to the varicella vaccine. The clinical significance of the postvaccine response is, however, unknown.
Further examination of the frail elderly participants indicated that increased Treg frequencies correlated with reduced varicella vaccine responsiveness. Regulatory T cells, which are known to suppress a variety of immune responses by both direct (eg, CTLA-4) and indirect (eg, interleukin 10) mechanisms [30] , were previously reported to limit vaccine responsiveness, partly through suppression of memory T-cell differentiation [31] . Furthermore, increased Treg frequencies were shown to be associated with reduced immunogenicity to influenza vaccination in human immunodeficiency virus-infected women [32] . The aforementioned studies, including our own, insinuate that the vaccine platforms for persons aged >60 years should incorporate suppression of Treg function to allow for better vaccination outcomes.
Unexpectedly, we found that the frequency of CMV-reactive CD4 + T cells from nursing home residents negatively correlated with vaccine responsiveness. In a study of a similar nursing home population, we also observed that the frequency of CMV-reactive CD4 + T cells correlated with an increased risk of respiratory tract infection [13] . Recent reports have shown that, for both young and old individuals, response to influenza vaccination was negatively associated with CMV seropositivity [33] [34] [35] . This is believed to occur due to a phenomenon known as memory inflation, in which an exhaustive proliferation of memory CMV-specific T cells occurs in the host as a means to control chronic CMV infection, even during latency, and results in the overpopulation of the immunological niche thus limiting space for other memory T cells [36] . Previous reports of the negative impact of CMV-reactive T cells on immunity in elderly individuals focused on CD8 + T cells. However, our results indicate that CMV-reactive CD4 + T cells, not CMVreactive CD8 + T cells, are a more relevant biomarker of immune responsiveness in the nursing home population. Although elderly residents of nursing homes exhibit markers of immunosenescence and, as such, are believed to have an impaired immune system, our report suggests that the live attenuated varicella vaccine can boost antiviral immunity. The vaccine-elicited booster responses could potentially lead to protective cellular immunity against VZV reactivation or at least limit the incidence and severity of HZ and thereby reduce the burden of disease. Importantly, we have shown that the liveattenuated Oka/Merck varicella vaccine is safe and comparably immunogenic in elderly nursing home residents, a population that is considered very old and frail. 
